Biotechnology & Immunology
Precision-engineered cytokines for organoid research
Amsbio has released a portfolio of over 30 cytokines specifi cally validated for organoid culture, providing researchers with high-performance reagents to support studies involving stem cells and induced pluripotent stem cells (iPSCs). Each cytokine has been independently developed and tested to ensure optimal activity, purity, and compatibility with established 3D cell culture protocols.
Organoids are increasingly central to research in developmental biology, disease modelling, regenerative medicine, and drug discovery. By recreating the structural and functional complexity of tissues in vitro, they offer a physiologically relevant alternative to traditional cell lines. However, the success and reproducibility of organoid systems depend heavily on the quality and consistency of the cytokines that regulate cell signalling, proliferation, and differentiation.
Amsbio’s cytokines – including Activin A, BMP-4, EGF, FGF-4, FGF-10, HGF, IGF1, Noggin, R-Spondin 1, Shh, and Wnt3a – are formulated with endotoxin levels below 0.01 EU/µg and validated in a range of in vitro organoid models. These include tumour organoids such as pituitary adenoma and breast cancer, as well as normal organoids derived from human iPSCs, intestine, and pancreas.
Supplied in ready-to-use formulations, the cytokines enable rapid organoid formation within 4–7 days while preserving tissue-specifi c architecture and genetic integrity. Their batch-to-batch consistency supports reliable, reproducible data across experiments, accelerating translational research and precision medicine applications.
More information online:
ilmt.co/PL/b8dG 66037pr@reply-direct.com
Streamlined pipetting accelerates molecular testing
QIAGEN Genomic Services has adopted Integra Biosciences’ handheld and benchtop electronic pipetting solutions to streamline PCR sample preparation, improving both throughput and reproducibility in its molecular testing workflows. By integrating these systems, the laboratory is helping customers accelerate the development of reliable methods for disease diagnosis, prevention, and treatment.
Based in Hilden, Germany, the Genomic Services team provides sample-to-insight testing for clients worldwide. Its flexible ‘fee-for-service’ model spans initial sample processing through to comprehensive analytical reporting, making use of diverse extraction kits and technologies to address different project requirements.
For Dr David Löper, Head of the laboratory, adaptability is key: “We are constantly evolving our workflows to handle a wide variety of samples and meet customer needs. This led us to seek versatile pipetting solutions that reduce manual steps while enhancing efficiency.”
Incoming biological samples arrive in tube format and are reformatted to 96-well filter plates using an ASSIST PLUS pipetting robot in combination with VOYAGER electronic pipettes. For nucleic acid extraction, the laboratory employs a VIAFLO 96 handheld electronic pipette. Compared with earlier centrifugation-based methods, this workflow is considerably faster and simpler, while also reducing tedious manual handling. The addition of the ASSIST PLUS instrument has further improved reproducibility across liquid transfer steps.
Dr Löper added: “These instruments have had a clear impact on both productivity and consistency, which is essential for managing high throughput genomics workflows and ensuring timely project delivery for our customers.”
More information online:
ilmt.co/PL/QK3X 65778pr@reply-direct.com
New offerings expand GMP capabilities for cell and gene therapy
Lonza has added new solutions to its TheraPEAK® portfolio, introducing AmpliCell® Cytokines and 293-GT® Medium to support scalable, high-performance workfl ows for cell and gene therapy. These offerings are designed to streamline processes from research through GMP production, helping scientists and manufacturers accelerate development timelines.
TheraPEAK® AmpliCell® Cytokines provide consistent, biologically active molecules that enhance immune cell expansion, activation, and differentiation. Produced in mammalian systems, they maintain native-like structure and function, ensuring reproducibility across batches - an essential factor in sensitive research and clinical applications.
TheraPEAK® 293-GT® Medium is a chemically defi ned, animal-free system optimised for AAV production in suspension HEK293 cells. Compatible with standard transfection reagents and AAV enhancers, it supports high viral titres and favourable capsid ratios, offering a scalable, drop-in solution for gene therapy programs.
These additions build on TheraPEAK®’s proven track record, already used in FDA-approved therapies and more than 130 clinical trials worldwide, delivering regulatory-ready solutions for both discovery and production stages.
More information online:
ilmt.co/PL/yWpG 66056pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64
